Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
L'enllaç es desa al porta-retalls
EstatEncara no heu contractat
Patrocinadors
University of Colorado Denver School of Medicine Barbara Davis Center

Paraules clau

Resum

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials.
The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.

Dates

Darrera verificació: 04/30/2020
Primer enviat: 05/18/2020
Inscripció estimada enviada: 05/26/2020
Publicat per primera vegada: 05/28/2020
Última actualització enviada: 05/26/2020
Publicació de l'última actualització: 05/28/2020
Data d'inici de l'estudi real: 06/30/2020
Data estimada de finalització primària: 06/29/2022
Data estimada de finalització de l’estudi: 12/30/2022

Condició o malaltia

Polycystic Kidney Disease, Adult
Polycystic Kidney, Autosomal Dominant

Intervenció / tractament

Drug: Adults with autosomal dominant polycystic kidney disease

Drug: Adults with autosomal dominant polycystic kidney disease

Radiation: Adults with autosomal dominant polycystic kidney disease

Fase

-

Grups de braços

BraçIntervenció / tractament
Adults with autosomal dominant polycystic kidney disease
All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
Drug: Adults with autosomal dominant polycystic kidney disease
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Healthy Controls
Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).

Criteris d'elegibilitat

Edats elegibles per estudiar 18 Years Per a 18 Years
Sexes elegibles per estudiarAll
Mètode de mostreigProbability Sample
Accepta voluntaris saludables
Criteris

Inclusion Criteria:

- Patients with Autosomal dominant polycystic kidney disease

- Age 18-40 years

- BMI >= 18.5 and <30 kg/m2

- Weight <350 lbs

Exclusion Criteria:

- Diabetes mellitus, based on previous diagnosis

- Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) <75ml/min/1.73m2

- Pregnancy or nursing

- Anemia

- Allergy to shellfish or iodine

- Vaptan therapy (e.g. tolvaptan)

- Uncontrolled hypertension (average ≥140/90 mmHg)

Resultat

Mesures de resultats primaris

1. Renal oxygen consumption [30 minutes]

11-C Acetate PET/CT

2. Insulin Sensitivity [4.5 hours]

Hyperinsulinemic-Euglycemic Clamp

Mesures de resultats secundaris

1. Mitochondrial Function [5 minutes]

Blood draw for mitochondrial DNA copy number

2. Mitochondrial Function [5 minutes]

Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle

3. Mitochondrial Function [5 minutes]

Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel

4. Mitochondrial Function [5 minutes]

Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation

5. Glomerular Filtration Rate (GFR) [3 hours]

Iohexol Clearance Study

6. Effective Renal Plasma Flow (ERPF) [2.5 hours]

PAH Clearance Study

7. Renin-Angiotensin-Aldosterone-System Activity [5 minutes]

Blood draw for Plasma Renin levels

8. Renin-Angiotensin-Aldosterone-System Activity [5 minutes]

Blood draw for Angiotensin II levels

9. Renin-Angiotensin-Aldosterone-System Activity [5 minutes]

Blood draw for Copeptin levels

10. Kidney Injury Biomarkers [5 minutes]

Chitinase-3-like protein 1 (YKL-40) levels

11. Kidney Injury Biomarkers [5 minutes]

Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels

12. Kidney Injury Biomarkers [5 minutes]

Blood draw for Kidney Injury Molecule 1 (KIM-1) levels

13. Kidney Injury Biomarkers [5 minutes]

Blood draw for Interleukin-18 (IL-18) levels

14. Kidney Injury Biomarkers [5 minutes]

Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels

15. Kidney Injury Biomarkers [5 minutes]

Blood draw for monocyte chemoattractant protein-1 (MCP-1) levels

Uneix-te a la nostra
pàgina de Facebook

La base de dades d’herbes medicinals més completa avalada per la ciència

  • Funciona en 55 idiomes
  • Cures a base d'herbes recolzades per la ciència
  • Reconeixement d’herbes per imatge
  • Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
  • Llegiu publicacions científiques relacionades amb la vostra cerca
  • Cerqueu herbes medicinals pels seus efectes
  • Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades

Google Play badgeApp Store badge